Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
U.S. FDA clears use of automated scanning system for PathVysion DNA
January 27th, 2005
The U.S. Food and Drug Administration (FDA) has cleared for marketing Abbott's Vysis AutoVysion System for use with the Vysis PathVysion HER-2 DNA Probe Kit as an aid in determining HER-2 gene status in women who have been diagnosed with breast cancer. AutoVysion, developed in collaboration with MetaSystems, GmbH, is designed to be used with Abbott's proprietary fluorescence in situ hybridization (FISH) technology and utilizes an automated scanning microscope and computer-assisted imaging system to aid in the detection and counting of FISH signals from breast cancer tissue sections. It is intended for laboratory use as an accessory to PathVysion, a...
Source: Women's Health Weekly (2005-01-27)
|
